Evidence map›Paper›PMID 35496863›Full record

ArticleRSC advances2021

Newly designed analogues from SARS-CoV inhibitors mimicking the druggable properties against SARS-CoV-2 and its novel variants.

Nadim Ferdous, Mahjerin Nasrin Reza, Md Shariful Islam, Md Tabassum Hossain Emon, A K M Mohiuddin, Mohammad Uzzal Hossain

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in RSC advances, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Nadim FerdousDepartment of Biotechnology and Genetic Engineering, Faculty of Life Science, Mawlana Bhashani Science and Technology University Santosh Tangail-1902 Bangladesh.
Mahjerin Nasrin RezaDepartment of Biotechnology and Genetic Engineering, Faculty of Life Science, Mawlana Bhashani Science and Technology University Santosh Tangail-1902 Bangladesh.
Md Shariful IslamDepartment of Biology, University of Kentucky 101 T.H. Morgan Building Lexington KY 40506-022 USA.ORCID https://orcid.org/0000-0002-7631-882X
Md Tabassum Hossain EmonDepartment of Biotechnology and Genetic Engineering, Faculty of Life Science, Mawlana Bhashani Science and Technology University Santosh Tangail-1902 Bangladesh.
A K M MohiuddinDepartment of Biotechnology and Genetic Engineering, Faculty of Life Science, Mawlana Bhashani Science and Technology University Santosh Tangail-1902 Bangladesh.
Mohammad Uzzal HossainBioinformatics Division, National Institute of Biotechnology Ganakbari, Ashulia, Savar Dhaka-1349 Bangladesh uzzalbge10044@gmail.com.ORCID https://orcid.org/0000-0002-9957-122X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The emerging variants of SARS coronavirus-2 (SARS-CoV-2) have been continuously spreading all over the world and have raised global health concerns. The B.1.1.7 (United Kingdom), P.1 (Brazil), B.1.351 (South Africa) and B.1.617 (India) variants, resulting from multiple mutations in the spike glycoprotein (SGp), are resistant to neutralizing antibodies and enable increased transmission. Hence, new drugs might be of great importance against the novel variants of SARS-CoV-2. The SGp and main protease (M

Identifiers

PMID35496863
PMCPMC9041434

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.